MTIP
JAZZ icon

Magee Thomson Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Magee Thomson Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-71,300
Closed -$10.1M – 98
2016
Q2 		$10.1M Buy
71,300
+7,250
+11% +$1.07M 3.52% 16
2016
Q1 		$8.36M Sell
64,050
-1,270
-2% -$158K 2.64% 21
2015
Q4 		$9.18M Buy
65,320
+730
+1% +$101K 2.53% 22
2015
Q3 		$8.58M Buy
64,590
+4,400
+7% +$758K 2.64% 21
2015
Q2 		$10.6M Sell
60,190
-27,180
-31% -$4.88M 3.07% 20
2015
Q1 		$15.1M Sell
87,370
-3,340
-4% -$573K 3.65% 14
2014
Q4 		$14.9M Buy
90,710
+15,500
+21% +$2.57M 3.69% 13
2014
Q3 		$12.1M Buy
75,210
+73,970
+5,965% +$11.4M 2.97% 18
2014
Q2 		$183K Hold
1,240
– – 0.04% 70
2014
Q1 		$173K Hold
1,240
– – 0.04% 74
2013
Q4 		$158K Sell
1,240
-796
-39% -$82.4K 0.04% 81
2013
Q3 		$188K Hold
2,036
– – 0.04% 67
2013
Q2 		$141K Buy
+2,036
New +$124K 0.03% 77

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Magee Thomson Investment Partners's JAZZ Position: Q3 2016 in Review

Magee Thomson Investment Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 71,300 shares — an estimated $10.1M sold.

Magee Thomson Investment Partners first reported a position in JAZZ in Q2 2013 and held it in 13 quarters. The position peaked at $15.1M in Q1 2015. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

  • Magee Thomson Investment Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 71,300 Jazz Pharmaceuticals shares in Q3 2016, an estimated $10.1M.
  • Magee Thomson Investment Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Magee Thomson Investment Partners's Jazz Pharmaceuticals position peaked at $15.1M in Q1 2015.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q3 2016, filed 27 Oct 2016.